|
54. Plasmapheresis and IVIG
- Rock GA, Shumak KH, Buskard NA, et al.
- Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.
N Engl J Med. 1991;325:393-7.
Description: Randomized trial of 102 patients demonstrating the benefit of plasmapheresis for treatment of TTP.
PubMed citation number: 2062330
- Reimann PM and Mason PD.
- Plasmapheresis: technique and complications.
Intensive Care Med. 1990;16:3-10.
Description: Concise review on the principles and different techniques of plasmapheresis.
PubMed citation number: 2179349
- Clark WF, Rock GA, Buskard NA, et al.
- Therapeutic plasma exchange: an update from the Canadian Apheresis Group.
Ann Intern Med. 1999;131:453-62.
Description: Reviews the five most common usages of plasma exchange in Canada from 1981 to 1997.
PubMed citation number: 10498563
- Knezevic-Maramica I and Kruskall MS.
- Intravenous immune globulins: an update for clinicians.
Transfusion. 2003;43:1460-80.
Description: Concise clinical review on the usages and adverse effects of IVIG.
PubMed citation number: 14507280
- Sewell WAC and Jolles S.
- Immunomodulatory action of intravenous immunoglobulin.
Immunology. 2002;107:387-93.
Description: Concise review on the mechanisms of action of IVIG.
PubMed citation number: 12460182
- Buckley RH and Schiff RI.
- The use of intravenous immune globulin in immunodeficiency diseases.
N Engl J Med. 1991;325:110-7.
PubMed citation number: 2052044
- Blanchette V and Carcao M
- Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura.
Transfus Sci. 1998;19:279-88.
Description: Clinical review on the mechanisms and clinical indications of IVIG and anti-D for ITP.
PubMed citation number: 10351140
- Kazatchkine MD and Kaveri SV.
- Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
N Engl J Med. 2001;345:747-55.
PubMed citation number: 11547745
- Yu Z and Lennon VA.
- Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.
N Engl J Med. 1999;340:227-8.
Description: Brief paper that describes the role of the FcRn receptor in IgG modulation.
PubMed citation number: 9895405
- Bleeker WK, Teeling JL and Hack CE.
- Accelerated auto-antibody clearance by intravenous immunoglobulin therapy. Studies in experimental models to determine the magnitude and time course of the effect.
Blood. 2001;98:3136-42.
PubMed citation number: 11698302
- Nydegger UE and Sturzenegger M.
- Adverse effects of intravenous immunoglobulin therapy.
Drug Safety. 1999;21:171-85.
Description: Comprehensive review on the different adverse effects associated with IVIG.
PubMed citation number: 10487396
- Bussel JB, Kimberly RP, Inman RD et al.
- Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura.
Blood. 1983;62:480-6.
Description: One of the first clinical trials using IVIG for ITP.
PubMed citation number: 6191803
- Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J. and Emerson, S. G.
- (1999). "Prevention of graft versus host disease by inactivation of host antigen-presenting cells." Science 285(5426): 412-5. PMID: 10411505.
In a mouse model of allogeneic BMT, only host antigen presenting cells are required for initiation of GVHD.
Solid Tumors and BMT
- Curtis, R. E., Rowlings, P. A., Deeg, H. J., Shriner, D. A., Socie, G., Travis, L. B., Horowitz, M. M., Witherspoon, R. P., Hoover, R. N., Sobocinski, K. A., Fraumeni, J. F., Jr. and Boice, J. D., Jr.
- (1997). "Solid cancers after bone marrow transplantation." N Engl J Med 336(13): 897-904. PMID: 9070469.
A study of 19,229 allogeneic/syngeneic transplant patients showing an increased risk of development of solid tumors.
- Stadtmauer, E. A., O'Neill, A., Goldstein, L. J., Crilley, P. A., Mangan, K. F., Ingle, J. N., Brodsky, I., Martino, S., Lazarus, H. M., Erban, J. K., Sickles, C. and Glick, J. H.
-
(2000). "Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer". N Engl J Med 342(15): 1069-76. PMID: 10760307.
The study that showed no survival benefit for autoBMT over conventional chemotherapy in metestatic breast cancer.
Non-myeloablative transplant
- Khouri, I. F., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A. and Champlin, R.
-
(1998). "Transplant-lite: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic
blood progenitor-cell transplantation as treatment for lymphoid malignancies." J Clin Oncol 16(8): 2817-24. PMID: 9704734.
An early description of non-myeloablative transplant for CLL/lymphoma.
- Antin, J. H. and J. L. Ferrara.
-
(1992). "Cytokine dysregulation and acute graft versus-
host disease." Blood 80(12): 2964-8. PMID: 1467511
- Champlin, R., Khouri, I., Komblau, S., Molidrem, J. and Giralt, S.
-
(1999). "Reinventing bone marrow transplantation.
Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect." Oncology (Huntingt) 13(5): 621-8; discussion 631, 635-8, 641. PMID: 10356683.
- Ho, V. T. and R. J. Soiffer.
-
(2001). "The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation." Blood 98(12): 3192-204. PMID: 11719354.
- Korbling, M. and P. Anderlini.
- (2001). "Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?" Blood 98(10): 2900-8. PMID: 11698269.
- Vogelsang, G.B.
-
(2001). "How I treat chronic graft-versus-host disease." Blood 97(5): 1196-201. PMID: 11222360.
|
